SION — Sionna Therapeutics, Inc.
Price · 2025-02-07 → 2026-08-21
386 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2025-02-07.
Performance
Technicals
Others in Healthcare
Measured signals that fired on SION
| date | signal | measured base rate |
|---|---|---|
| 2026-08-10 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-08-10 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-08-04 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-08-04 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-07-17 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-06-08 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-07 | ORBIMED ADVISORS LLC Director | Open-market sale 10b5-1 plan | 85.9K | 44.86 | 3.9M |
| 2026-07-07 | Thompson Peter A. Director | Open-market sale 10b5-1 plan | 85.9K | 44.86 | 3.9M |
| 2026-07-07 | OrbiMed Capital GP VIII LLC Director | Open-market sale 10b5-1 plan | 85.9K | 44.86 | 3.9M |
| 2026-07-06 | Fitzpatrick Jennifer Chief Legal Officer | Open-market sale 10b5-1 plan | 10.2K | 43.60 | 446.9K |
| 2026-07-06 | Fitzpatrick Jennifer Chief Legal Officer | Option exercise 10b5-1 plan | 10.2K | 6.11 | 62.6K |
| 2026-06-30 | OrbiMed Capital GP VIII LLC Director | Open-market sale 10b5-1 plan | 115.8K | 45.50 | 5.3M |
| 2026-06-30 | ORBIMED ADVISORS LLC Director | Open-market sale 10b5-1 plan | 115.8K | 45.50 | 5.3M |
| 2026-06-30 | Thompson Peter A. Director | Open-market sale 10b5-1 plan | 115.8K | 45.50 | 5.3M |
| 2026-05-27 | OrbiMed Capital GP VIII LLC Director | Open-market sale 10b5-1 plan | 101 | 44.49 | 4.5K |
| 2026-05-27 | ORBIMED ADVISORS LLC Director | Open-market sale 10b5-1 plan | 101 | 44.49 | 4.5K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 397.1M | 9.9M |
| TPG GP A, LLC | 260.4M | 6.5M |
| ORBIMED ADVISORS LLC | 141.5M | 3.5M |
| VIKING GLOBAL INVESTORS LP | 128.1M | 3.2M |
| Atlas Venture Life Science Advisors, LLC | 120.1M | 3.0M |
| ENAVATE SCIENCES GP, LLC | 99.3M | 2.5M |
| JENNISON ASSOCIATES LLC | 58.2M | 1.5M |
| JPMORGAN CHASE & CO | 53.7M | 1.5M |
| BlackRock, Inc. | 52.0M | 1.3M |
| CITADEL ADVISORS LLC | 46.8M | 1.2M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 8-K | 2026-08-10 | 2026-08-10 | on EDGAR ↗ |
| 10-Q | 2026-08-06 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
| 4 | 2026-07-09 | 2026-07-07 | on EDGAR ↗ |
| 4 | 2026-07-09 | 2026-07-07 | on EDGAR ↗ |
| 4 | 2026-07-07 | 2026-07-06 | on EDGAR ↗ |
| 144 | 2026-07-06 | — | on EDGAR ↗ |
| 4 | 2026-07-02 | 2026-06-30 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics · 2026-08-20
- Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky · 2026-08-19
- SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics · 2026-08-13
- SION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm · 2026-08-13
- Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION) · 2026-08-12
- Why is Sionna Therapeutics stock collapsing today? · 2026-08-10
Ask the AI about SION
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →